Ingavirin®

Brand Valenta

In stock 1107 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Ingavirin - antiviral anti-inflammatory agent.

Ingavirin has antiviral effect, is effective against influenza A viruses (A / H1 N1, including swine A / H1 N1 swl, A / H3N2, A / H5N1), type B, adenoviral infection, parainfluenza, respiratory - syncytial infection. The antiviral mechanism of action is associated with the suppression of viral reproduction during the nuclear phase, the delayed migration of the newly synthesized NP virus from the cytoplasm into the nucleus.

It has a modulating effect on the functional activity of the interferon system: causes an increase in the content of interferon in the blood to the physiological norm, stimulates and normalizes the reduced a-interferon-producing ability of blood leukocytes, stimulates the u-interferon-producing ability of leukocytes.

It causes the generation of cytotoxic lymphocytes and increases the content of NK-T cells with high killer activity against viral-transformed cells and pronounced antiviral activity.

The anti-inflammatory effect of Ingavirin is due to the suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-a), interleukins (IL-1B and IL-6)), a decrease in myeloperoxidase activity.

Therapeutic efficacy in influenza and other acute respiratory viral infections (ARVI) is manifested in shortening the period of fever, reducing intoxication (headache, weakness, dizziness), catarrhal phenomena, reducing the number of complications and the duration of the disease as a whole.

Experimental toxicological studies indicate a low level of toxicity and a high safety profile of the drug (LD50 exceeds therapeutic dose more than 3000 times). The drug does not have mutagenic, immunotoxic, allergenic and carcinogenic properties, does not have a local irritating effect. IngavirinR does not affect reproductive function, does not have embryotoxic and teratogenic effects.

Indications

Treatment and prevention of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection).

Composition

One capsule contains:
Active substance: imidazolylethanamide pentanediic acid (vitagluta) in terms of 100% substance - 90 mg.
Excipients:
lactose (milk sugar), potato starch, colloidal silicon dioxide (aerosil), magnesium stearate. Hard gelatin capsules (titanium dioxide, gelatin).
The composition of the capsule shell: titanium dioxide, quinoline yellow azorubine, crimson dye (Ponso 4R), gelatin.

No customer reviews for the moment.

Write your review

Dosage and Administration

For oral use. Regardless of the meal.

At 90 mg once a day, 5-7 days (depending on the severity of the condition).

For the prevention of influenza and acute respiratory viral infections after contact with sick persons: 90 mg 1 time per day for 7 days.

The drug is started from the moment the first symptoms of the disease appear, preferably not later than 36 hours from the onset of the disease.

Adverse reactions

Allergic reactions (rare).

Contraindications

Individual intolerance to the components of the drug, pregnancy, children under 18 years of age.

Drug interactions

The simultaneous use of Ingavirin with other antiviral drugs is not recommended.
There were no cases of Ingavirin interaction with other drugs.

Pregnancy and Lactation

The use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, therefore, if necessary, use of the drug during lactation should stop breastfeeding.

Special instructions

The drug does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in people of various professions, including requiring increased attention and coordination of movements. The simultaneous use of other antiviral drugs is not recommended.